| CME |
Report |
Adjusted diluted EPS |
MISS |
pred ~$2.89 vs. cons $2.96 |
MEDIUM |
| CME |
Report |
Total revenue |
MISS |
pred ~$1.67B vs. cons $1.72B |
MEDIUM |
| CME |
Report |
Clearing and transaction-fee revenue |
MISS |
pred ~$1.33B vs. cons $1.38B |
MEDIUM |
| CME |
Guide |
Adjusted operating expense excluding license fees |
UNCHANGED |
guide ~$1.695B vs. cons $1.695B (FY2026) |
HIGH |
| CME |
Guide |
Implied 2H26 adjusted operating expense excluding license fees |
LOWER |
guide ~$0.85B vs. cons $0.87B (2H2026) |
MEDIUM |
| CME |
Guide |
July average daily volume commentary |
BETTER |
guide ~31.0M contracts vs. cons 30.5M contracts (July 2026) |
LOW |
| CME |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.8% |
— |
MEDIUM |
| CME |
Return |
5-day cumulative residual |
-3.6% (FOLLOW-THROUGH) |
A modest headline revenue/EPS miss is likely to be compounded by lower rate-per-contract and clearing-fee expectations; unchanged full-year expense guidance limits downside but does not offset negative out-period revenue and EPS revisions. |
MEDIUM |